R274
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 69
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.350
- MYC_TARGETS_V2+0.240
- ANDROGEN_RESPONSE+0.110
- PANCREAS_BETA_CELLS+0.110
- PROTEIN_SECRETION+0.100
- ANGIOGENESIS+0.050
- OXIDATIVE_PHOSPHORYLATION+0.040
- SPERMATOGENESIS+0.040
- HEDGEHOG_SIGNALING+0.030
- KRAS_SIGNALING_DN+0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.600
- IL6_JAK_STAT3_SIGNALING-0.530
- INFLAMMATORY_RESPONSE-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- ALLOGRAFT_REJECTION-0.400
- APOPTOSIS-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- COMPLEMENT-0.370
- IL2_STAT5_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 84ca3236-683a-40f6-b8a6-600ffd43a0da | — | — | 0.889 |
| 2 | SRR8518374 | — | E | 0.869 |
| 3 | SRR5088919 | — | — | 0.865 |
| 4 | a277c487-2d13-460f-a0d8-26acac1657d0 | — | — | 0.842 |
| 5 | f0a22b8b-4cf5-4edc-9502-1e01839fa7c7 | — | — | 0.842 |
| 6 | bbba6e8b-9e37-45e0-b663-f81631e76828 | — | — | 0.842 |
| 7 | BS_YEB88D32 | Med | Medulloblastoma | 0.841 |
| 8 | e97f9781-5033-40bd-bc5c-7a703ef965b1 | — | — | 0.838 |
| 9 | MBCProject_0297_T1_RNA | — | A | 0.836 |
| 10 | SRR8518365 | — | E | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |